Ali Satvat - BridgeBio Pharma, Independent Director
| 2CL Stock | EUR 29.53 0.68 2.25% |
Insider
Ali Satvat is Independent Director of BridgeBio Pharma, since 2016.
| Age | 41 |
| Tenure | 9 years |
| Phone | 650 391 9740 |
| Web | http://www.bridgebio.com |
BridgeBio Pharma, Management Efficiency
The company has return on total asset (ROA) of (31.81) % which means that it has lost $31.81 on every $100 spent on assets. This is way below average. BridgeBio Pharma,'s management efficiency ratios could be used to measure how well BridgeBio Pharma, manages its routine affairs as well as how well it operates its assets and liabilities.BridgeBio Pharma, has accumulated 1.4 B in total debt with debt to equity ratio (D/E) of 4.61, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BridgeBio Pharma, has a current ratio of 6.76, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist BridgeBio Pharma, until it has trouble settling it off, either with new capital or with free cash flow. So, BridgeBio Pharma,'s shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BridgeBio Pharma, sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BridgeBio to invest in growth at high rates of return. When we think about BridgeBio Pharma,'s use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Sue Farr | ACCSYS TECHPLC EO | N/A | |
| Hiroyuki Tsuruta | Sanyo Chemical Industries | N/A | |
| Christoph Khne | Easy Software AG | N/A | |
| Stephan Pauler | Easy Software AG | N/A | |
| Heino Erdmann | Easy Software AG | 56 | |
| Akinori Higuchi | Sanyo Chemical Industries | 64 | |
| Nhi Stein | Easy Software AG | N/A | |
| Trudy Schoolenberg | ACCSYS TECHPLC EO | 58 | |
| Nick Meyer | ACCSYS TECHPLC EO | 69 | |
| Yuichi Fujii | Sanyo Chemical Industries | N/A | |
| Andreas Zipser | Easy Software AG | N/A | |
| Angus Dodwell | ACCSYS TECHPLC EO | N/A | |
| Patrick Shanley | ACCSYS TECHPLC EO | 65 | |
| Thomas Cziesla | Easy Software AG | N/A | |
| Masahiro Fukui | Sanyo Chemical Industries | N/A | |
| Kohei Maeda | Sanyo Chemical Industries | 63 | |
| Hiroyuki Shimominami | Sanyo Chemical Industries | 63 | |
| Hiroyuki Susaki | Sanyo Chemical Industries | N/A | |
| Masahiro Harada | Sanyo Chemical Industries | N/A | |
| Stephen Odell | ACCSYS TECHPLC EO | 64 | |
| Kinya Ito | Sanyo Chemical Industries | N/A | |
Management Performance
| Return On Asset | -31.81 |
BridgeBio Pharma, Leadership Team
Elected by the shareholders, the BridgeBio Pharma,'s board of directors comprises two types of representatives: BridgeBio Pharma, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BridgeBio. The board's role is to monitor BridgeBio Pharma,'s management team and ensure that shareholders' interests are well served. BridgeBio Pharma,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BridgeBio Pharma,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Neil Kumar, Chief Executive Officer, Director | ||
| Richard Scheller, Chairman of Research and Development, Director | ||
| Michael Henderson, Chief Business Officer | ||
| Andrew Lo, Independent Director | ||
| Randal Scott, Independent Director | ||
| Uma Sinha, Chief Scientific Officer | ||
| Brenton Saunders, Independent Director | ||
| Jennifer Cook, Independent Director | ||
| Brian Stephenson, Chief Financial Officer, Principal Accounting Officer | ||
| Ali Satvat, Independent Director | ||
| Cameron Turtle, Senior Vice President - Portfolio Management and Corporate Development | ||
| James Momtazee, Independent Director | ||
| Eric Aguiar, Independent Director | ||
| Charles Homcy, Chairman of Pharmaceuticals, Lead Director | ||
| Ronald Daniels, Independent Director | ||
| Frank Mccormick, Chairman of Oncology |
BridgeBio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BridgeBio Pharma, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -31.81 | |||
| Operating Margin | (806.01) % | |||
| Current Valuation | 6.62 B | |||
| Shares Outstanding | 149.28 M | |||
| Shares Owned By Insiders | 7.47 % | |||
| Shares Owned By Institutions | 96.18 % | |||
| Price To Book | 108.28 X | |||
| Price To Sales | 100.89 X | |||
| Revenue | 62.73 M | |||
| Gross Profit | 8.25 M |
Currently Active Assets on Macroaxis
Other Information on Investing in BridgeBio Stock
BridgeBio Pharma, financial ratios help investors to determine whether BridgeBio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BridgeBio with respect to the benefits of owning BridgeBio Pharma, security.